Literature DB >> 3117843

Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

R N Jones1, A L Barry.   

Abstract

The ampicillin-sulbactam combination was evaluated in vitro to determine the optimal susceptibility testing conditions among five combination ratios and four fixed concentrations of sulbactam. The organisms tested were markedly resistant to aminopenicillins and most other beta-lactams. The ratio of 2:1 is recommended to assure recognition of the ampicillin-sulbactam spectrum and minimize false-susceptible results among strains known to be resistant to this combination. Proposed MIC breakpoint concentrations were compatible with levels in serum achieved with recommended clinical doses. Cross-resistance analyses comparing ampicillin-sulbactam and amoxicillin-clavulanate showed comparable activity and spectra. However, the major interpretive disagreement was sufficient to require separate testing of these aminopenicillin-inhibitor combinations. The recommended ampicillin-sulbactam MIC susceptibility breakpoints are as follows: (i) less than or equal to 8.0/4.0 micrograms/ml for tests against members of the family Enterobacteriaceae, anaerobes, nonenteric gram-negative bacilli, staphylococci, Haemophilus influenzae, and Branhamella catarrhalis; (ii) the ampicillin MICs alone interpreted by National Committee for Clinical Laboratory Standards criteria should predict ampicillin-sulbactam susceptibility for the enterococci, streptococci, and Listeria monocytogenes. MIC quality control ranges were determined by multiple laboratory broth microdilution trials for the ampicillin-sulbactam 1:1 and 2:1 ratio tests.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117843      PMCID: PMC269368          DOI: 10.1128/jcm.25.10.1920-1925.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

2.  Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

3.  Plasmid-determined beta-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; C Fuster; R Reig
Journal:  J Antimicrob Chemother       Date:  1983-11       Impact factor: 5.790

4.  Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

5.  Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  J Bacteriol       Date:  1984-05       Impact factor: 3.490

Review 6.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits.

Authors:  P C Fuchs; A L Barry; C Thornsberry; T L Gavan; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  14 in total

1.  Antibacterial activity of N-benzylsalicylthioamides.

Authors:  E Petrlíková; K Waisser; P Jílek; I Dufková
Journal:  Folia Microbiol (Praha)       Date:  2010-10-13       Impact factor: 2.099

2.  Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli.

Authors:  E M O'Shaughnessy; G A Fahle; F G Witebsky
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

4.  Susceptibility of Haemophilus influenzae type b to ampicillin-sulbactam.

Authors:  P H Azimi; M G Dunphy
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 6.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

8.  In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Examination of bacterial inhibition using a catalytic DNA.

Authors:  Long Qu; M Monsur Ali; Sergio D Aguirre; Hongxia Liu; Yuyang Jiang; Yingfu Li
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

10.  Ureidopyrazine Derivatives: Synthesis and Biological Evaluation as Anti-Infectives and Abiotic Elicitors.

Authors:  Ghada Bouz; Martin Juhás; Pavlína Niklová; Ondřej Janďourek; Pavla Paterová; Jiří Janoušek; Lenka Tůmová; Zuzana Kovalíková; Petr Kastner; Martin Doležal; Jan Zitko
Journal:  Molecules       Date:  2017-10-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.